ArticleJournal of experimental & clinical cancer research : CR2020
NUCKS promotes cell proliferation and suppresses autophagy through the mTOR-Beclin1 pathway in gastric cancer.
Article in Journal of experimental & clinical cancer research : CR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 35 citations in OpenAlex.
- Cell-Type-Resolved Proteomics Reveals Distinct Immune and Metabolic Programs Between Primary and Recurrent Ascites in HGSOC.Proteomics. Clinical applications · 2026Article
- NUCKS1 promotes invasion and metastasis of colorectal cancer by stabilizing HDAC2 and activating AKT.Oncogenesis · 2025Article
- Targeting NUCKS1 with a fragment of tRNANon-coding RNA research · 2025Article
- In vitro analysis of the molecular mechanisms of ursolic acid against ovarian cancer.BMC complementary medicine and therapies · 2025Article
- NUCKS1 exacerbates hepatocellular carcinoma cell proliferation and metastasis via the upregulation of Cdc42.American journal of cancer research · 2025Article
- Histone demethylase KDM4B accelerates the progression of glioblastoma via the epigenetic regulation of MYC stability.Clinical epigenetics · 2023Article
- Roles of increased NUCKS1 expression in endometriosis.BMC women's health · 2023Article
- NUCKS1, a LINC00629-upregulated gene, facilitated osteosarcoma progression and metastasis by elevating asparagine synthesis.Cell death & disease · 2023Article
- NRP1 regulates autophagy and proliferation of gastric cancer through Wnt/β-catenin signaling pathway.Aging · 2023Article
- Traditional Chinese medicine for transformation of gastric precancerous lesions to gastric cancer: A critical review.World journal of gastrointestinal oncology · 2023Review
- IL-17A regulates autophagy and promotes osteoclast differentiation through the ERK/mTOR/Beclin1 pathway.PloS one · 2023Article
- Selective dopaminergic vulnerability in Parkinson's disease: new insights into the role of DAT.Frontiers in neuroscience · 2023Review
- Beclin1- and Atg13-dependent autophagy activation and morroniside have synergistic effect on osteoblastogenesis.Experimental biology and medicine (Maywood, N.J.) · 2022Article
- Molecular Mechanisms of Autophagy in Cancer Development, Progression, and Therapy.Biomedicines · 2022Review
- NUCKS1 is a highly modified, chromatin-associated protein involved in a diverse set of biological and pathophysiological processes.The Biochemical journal · 2022Review
- Young fibroblast-derived exosomal microRNA-125b transfers beneficial effects on aged cutaneous wound healing.Journal of nanobiotechnology · 2022Article
- Development of a novel autophagy-related gene model for gastric cancer prognostic prediction.Frontiers in oncology · 2022Article
- Recent advances of the mammalian target of rapamycin signaling in mesenchymal stem cells.Frontiers in genetics · 2022Review
- Autophagy-related prognostic signature characterizes tumor microenvironment and predicts response to ferroptosis in gastric cancer.Frontiers in oncology · 2022Article
- The role of hypoxia-inducible factor-1 alpha in multidrug-resistant breast cancer.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundNuclear casein kinase and cyclin-dependent kinase substrate (NUCKS), a novel gene first reported in 2001, is a member of the high mobility group (HMG) family. Although very little is known regarding the biological roles of NUCKS, emerging clinical evidence suggests that the NUCKS protein can be used as a biomarker and therapeutic target in various human ailments, including several types of cancer.
methodsWe first assessed the potential correlation between NUCKS expression and gastric cancer prognosis. Then functional experiments were conducted to evaluate the effects of NUCKS in cell proliferation, cell cycle, apoptosis and autophagy. Finally, the roles of NUCKS on gastric cancer were examined in vivo.
resultsWe found that NUCKS was overexpressed in gastric cancer patients with poor prognosis. Through manipulating NUCKS expression, it was observed to be positively associated with cell proliferation in vitro and in vivo. NUCKS knockdown could induce cell cycle arrest and apoptosis. Then further investigation indicated that NUCKS knockdown could also significantly induce a marked increase in autophagy though the mTOR-Beclin1 pathway, which could be was rescued by NUCKS restoration. Moreover, silencing Beclin1 in NUCKS knockdown cells or adding rapamycin in NUCKS-overexpressed cells also confirmed these results.
conclusionsOur findings revealed that NUCKS functions as an oncogene and an inhibitor of autophagy in gastric cancer. Thus, the downregulation or inhibition of NUCKS may be a potential therapeutic strategy for gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.